Details for Patent: 9,611,267

Which drugs does patent 9,611,267 protect, and when does it expire?

Patent 9,611,267 protects PEMAZYRE and is included in one NDA.

This patent has one hundred and eleven patent family members in thirty-seven countries.

Summary for Patent: 9,611,267

Title:	Substituted tricyclic compounds as FGFR inhibitors
Abstract:	The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Inventor(s):	Wu; Liangxing (Wilmington, DE), Zhang; Colin (Ambler, PA), He; Chunhong (Chadds Ford, PA), Lu; Liang (Hockessin, DE), Yao; Wenqing (Chadds Ford, PA)
Assignee:	Incyte Holdings Corporation (Wilmington, DE) Incyte Corporation (Wilmington, DE)
Application Number:	13/915,775
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,611,267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-001	Apr 17, 2020		RX	Yes	No			Y	Y
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-002	Apr 17, 2020		RX	Yes	No			Y	Y
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-003	Apr 17, 2020		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,611,267

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	091424
Argentina	117823
Argentina	122006